CEPI Launches Additional Call for the Rapid Development of Vaccines Against COVID-19

CEPI Launches Additional Call for the Rapid Development of Vaccines Against COVID-19

Thursday, 7 May, 2020

In response to the ongoing COVID-19 pandemic and the resulting public health crisis, the Coalition for Epidemic Preparedness Innovations (CEPI) has launched a new call to achieve an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19.

CEPI is striving to accelerate vaccine development and to ensure that associated manufacturing capabilities and capacities will meet global demand as quickly as possible. This call for proposals will support the rapid development of vaccines striving for licensure/emergency authorisation in 12-18 months or less and, to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021. Applicants must apply for one lead COVID-19 vaccine candidate.

The call is being issued in conjunction with the establishment of the Access to COVID-19 Tools (ACT) Accelerator, a public-private partnership committed to speeding the development of and global access to diagnostics, therapeutics, and vaccines.

The call will be of potential interest to organisations who have already secured resources for a vaccine candidate for a given COVID-19 target indication or region, and now seek additional support to aid expansion of global development plans, support large clinical trials, and/or widen the geographical manufacturing footprint.

Applications are open worldwide to all types of non-profit research organisations, for-profit companies, international organisations and foundations, joint R&D ventures, government research organisations, and academic institutions. The main applicant, or for a consortium at least one of the members, must have experience in human vaccine development and have a track record of bringing vaccine candidates through development, ideally including licensure and manufacturing. In addition, the applicant should either be a manufacturer or have a manufacturer with a track record of vaccine production identified within the consortium.

This is a rolling call open until at least 30 June 2020. Applications will be rapidly reviewed in batches every two weeks. The call maybe extended if needed.

 

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.

 

other funding news

Our experienced content team is skilled at sourcing funding opportunities, reporting on the latest hot topics and providing accurate, comprehensive funding content which supports organisations and their beneficiaries in their quest for funding.

Interested in finding out more about
RESEARCHconnect and subscription fees?

RESEARCHconnect

Supporting you at every step of your funding journey